Clinical and laboratory monitoring
pneumonia
ADVERSE EVENTS, PNEUMONIA
Within 3 days after the last dosing, safety follow-up of subjects (including subjects who withdrew early) was completed, including: physical examination, vital signs collection, nucleic acid test of SARS-CoV-2, laboratory examination, 12-lead electrocardiogram examination, chest CT, blood gas analysis, pneumonia severity (PSI) examination, follow-up of adverse events, severe adverse events, and collection of combination therapy information.